Quince Therapeutics Inc (Quince) is a clinical-stage biopharmaceutical company that focused on novel therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company product pipeline includes NOV004. The company lead candidate NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site. Quince also runs clinical trails such as GAIN Trial, a Phase 2 and Phase 3 clinical trial of COR388 to moderate and treat Alzheimer’s disease. Quince is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
601 Gateway Boulevard, Suite 1250, South San Francisco, California, 94080
Website
quincetx.com
Telephone
1 415 9105717
No of Employees
21
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
QNCX (NASD)
EPS
XYZ
Net Income (2021)
XYZ
42.6%
(2021 vs 2020)
Market Cap*
$45.8M
* As of and is in US$
Quince Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Products Pipeline: |
| NOV004 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company announced the completion of its acquisition of EryDel S.p.A., a late-stage biotech company. |
| 2023 | Others | In March, the company received an offer to be acquired by Echo Lake Capital for US$58.8 million. |
| 2023 | Divestiture | In January, the company sold its legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803 to Lighthouse Pharmaceuticals. |
Competitor Comparison
| Key Parameters | Quince Therapeutics Inc | AbbVie Inc | Alector Inc | Acumen Pharmaceuticals Inc | Cenna Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | North Chicago | South San Francisco | Charlottesville | La Jolla |
| State/Province | California | Illinois | California | Virginia | California |
| No. of Employees | 21 | 50,000 | 244 | 51 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Lamond | Chairman | Executive Board | 2015 | 48 |
| Dirk Thye | Chief Executive Officer; Director | Executive Board | 2022 | 53 |
| Karen Smith | Chief Medical Officer | Senior Management | 2022 | 55 |
| Charles S. Ryan, Ph.D | President | Senior Management | 2023 | - |
| Brendan Hannah | Chief Business Officer; Principal Financial Officer | Senior Management | 2022 | 38 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward